An Approved Vaccine To Treat Prostate Cancer Has Few Side Effects

An Approved Vaccine To Treat Prostate Cancer Has Few Side Effects.
The newly approved medical prostate cancer vaccine, Provenge, is innocuous and has few position effects, a new study finds. In April, the US Food and Drug Administration approved the vaccine for use in men with advanced prostate cancer who had failed hormone therapy. "Provenge was approved based on both safeness and clinical data," said head researcher Dr Simon J Hall, chairman of urology at Mount Sinai Medical Center in New York City.

This sanctuary data shows that there are very limited side effects. The gain of the vaccine for patients with metastatic hormone-resistant prostate cancer is that it has fewer side slang shit than chemotherapy, which is the only other treatment option for these patients. In addition, Provenge has improved survival over chemotherapy.

The ordinary survival time for men given Provenge is 4,5 months, although some patients saw their lives extended by two to three years. "This is a newly close by treatment, with very limited surface effects, compared to anything else that a man would be considering in this state". Hall was to present the results on Monday at the American Urological Association annual assignation in San Francisco.

Data from four phase 3 trials, which included 904 men randomized to either Provenge or placebo, showed the vaccine extended survival, improved supremacy of freshness and had only mild side effects. In fact, more than 83 percent of the men who received Provenge were able to do appear as activities without any restrictions, the researchers noted.